BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32747627)

  • 1. An optimal posttreatment surveillance strategy for cancer survivors based on an individualized risk-based approach.
    Zhou GQ; Wu CF; Deng B; Gao TS; Lv JW; Lin L; Chen FP; Kou J; Zhang ZX; Huang XD; Zheng ZQ; Ma J; Liang JH; Sun Y
    Nat Commun; 2020 Aug; 11(1):3872. PubMed ID: 32747627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis.
    Liao W; Huang J; Wu Q; Zhu G; Wang X; Wen F; Zhang P; Zhang N; Li Q
    Oral Oncol; 2019 Jun; 93():15-20. PubMed ID: 31109691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal postoperative surveillance strategies for cancer survivors with gastric neuroendocrine carcinoma based on individual risk: a multicenter real-world cohort study.
    Xu BB; He XY; Zhou YB; He QL; Tian YT; Hao HK; Qiu XT; Jiang LX; Zhao G; Li Z; Xu YC; Fu WH; Xue FQ; Li SL; Xu ZK; Zhu ZG; Li Y; Li E; Chen JP; Li HL; Cai LS; Wu D; Li P; Zheng CH; Xie JW; Lu J; Huang CM
    Int J Surg; 2023 Jun; 109(6):1668-1676. PubMed ID: 37076132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA.
    Wu CF; Lin L; Mao YP; Deng B; Lv JW; Zheng WH; Wen DW; Kou J; Chen FP; Yang XL; Xu SS; Ma J; Zhou GQ; Sun Y
    BMC Med; 2021 Aug; 19(1):193. PubMed ID: 34433440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.
    Liu W; Yu B; Luo Y; Li J; Yuan X; Wu S; Liang B; Lv Z; Li Y; Peng X; Lu J; Peng X; Liu X
    BMC Cancer; 2021 May; 21(1):639. PubMed ID: 34051750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and validation of two nomograms to predict the benefit of concurrent chemotherapy in stage II-IVa nasopharyngeal carcinoma patients with different risk factors: Analysis based on a large cohort.
    Sun XS; Xiao BB; Lin C; Liu SL; Chen QY; Tang LQ; Mai HQ
    Cancer Med; 2020 Mar; 9(5):1661-1670. PubMed ID: 31925942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area.
    Yao JJ; Lin L; Gao TS; Zhang WJ; Lawrence WR; Ma J; Sun Y
    Cancer Res Treat; 2021 Jul; 53(3):657-670. PubMed ID: 33285052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
    Chen X; Liang W; Wan N; Zhang L; Yang Y; Jiang J; Zhang T
    Oral Oncol; 2019 Jul; 94():80-85. PubMed ID: 31178217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma.
    Fei Z; Xu T; Li M; Chen T; Li L; Qiu X; Chen C
    Radiat Oncol; 2020 Oct; 15(1):230. PubMed ID: 33008416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term complications and prognostic factors in locally advanced nasopharyngeal carcinoma treated with docetaxel, cisplatin, 5-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy: A retrospective cohort study.
    Shim HJ; Kim HJ; Hwang JE; Bae WK; Chung IJ; Lee DH; Mi YT; Lee JK; Lim SC; Chung JW; Cho SH
    Medicine (Baltimore); 2020 Dec; 99(49):e23173. PubMed ID: 33285692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.
    Zaidi MY; Lopez-Aguiar AG; Switchenko JM; Lipscomb J; Andreasi V; Partelli S; Gamboa AC; Lee RM; Poultsides GA; Dillhoff M; Rocha FG; Idrees K; Cho CS; Weber SM; Fields RC; Staley CA; Falconi M; Maithel SK
    Ann Surg; 2019 Sep; 270(3):422-433. PubMed ID: 31283562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma.
    Jin C; Zheng H; Zhan M; Wen F; Xu T
    Eur Arch Otorhinolaryngol; 2020 Feb; 277(2):577-584. PubMed ID: 31720816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion-weighted MRI for predicting treatment response in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis.
    Lee MK; Choi Y; Jung SL
    Sci Rep; 2021 Sep; 11(1):18986. PubMed ID: 34556743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
    Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
    Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of COX-2 expression on circulating tumor cells in nasopharyngeal carcinoma: A prospective analysis.
    Li YJ; Luo Y; Xie XQ; Li P; Wang F
    Radiother Oncol; 2018 Nov; 129(2):396-402. PubMed ID: 30082142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
    Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
    JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health and Economic Impact of Intensive Surveillance for Distant Recurrence After Curative Treatment of Colon Cancer: A Mathematical Modeling Study.
    Wanis KN; Maleyeff L; Van Koughnett JAM; H D Colquhoun P; Ott M; Leslie K; Hernandez-Alejandro R; Kim JJ
    Dis Colon Rectum; 2019 Jul; 62(7):872-881. PubMed ID: 31188189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.
    Li W; Chen J; Liang B; Li Z; Li J; Yuan X; Wu S; Zeng F; Peng X; Li Y; Lu J; Zhao F; Liu X
    Cancer Med; 2021 Feb; 10(3):883-894. PubMed ID: 33378109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
    Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
    Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of induction chemotherapy regimen TPF vs GP followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A retrospective cohort study of 160 patients.
    Guan H; He Y; Wei Z; Wang J; He L; Mu X; Peng X
    Clin Otolaryngol; 2020 Mar; 45(2):274-279. PubMed ID: 31788988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.